NATURE’S SUNSHINE PRODUCTS, INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2021-11-04
- NATURE’S SUNSHINE PRODUCTS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2021-06-30 was $0.00.
- NATURE’S SUNSHINE PRODUCTS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2021-03-31 was $0.00.
- NATURE’S SUNSHINE PRODUCTS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2020-12-31 was $298.00K.
- NATURE’S SUNSHINE PRODUCTS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2020-09-30 was -$88.00K.
- NATURE’S SUNSHINE PRODUCTS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2020 was $0.00.
- NATURE’S SUNSHINE PRODUCTS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2019 was -$320.00K.
- NATURE’S SUNSHINE PRODUCTS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2018 was -$675.00K.
- NATURE’S SUNSHINE PRODUCTS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | $298.00K derived: sum of 3 quarters · filed 2021-08-05 | $210.00K derived: sum of 4 quarters · filed 2021-11-04 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $298.00K derived: sum of 2 quarters · filed 2021-05-06 | $210.00K derived: sum of 3 quarters · filed 2021-11-04 | $159.00K derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-12-31 | $298.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $210.00K derived: sum of 2 quarters · filed 2021-11-04 | $159.00K derived: sum of 3 quarters · filed 2021-11-04 | $0.00 10-K · filed 2021-03-10 | |
| 2020-09-30 | -$88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$139.00K derived: sum of 2 quarters · filed 2021-11-04 | -$298.00K 10-Q · filed 2021-11-04 | -$425.00K derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$210.00K 10-Q · filed 2021-08-05 | -$337.00K derived: sum of 3 quarters · filed 2021-08-05 | -$337.00K derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$159.00K 10-Q · filed 2021-05-06 | -$286.00K derived: sum of 2 quarters · filed 2021-05-06 | -$286.00K derived: sum of 3 quarters · filed 2021-05-06 | -$290.00K derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | -$127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$127.00K derived: sum of 2 quarters · filed 2021-03-10 | -$131.00K derived: sum of 3 quarters · filed 2021-03-10 | -$320.00K 10-K · filed 2021-03-10 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$4.00K derived: sum of 2 quarters · filed 2020-11-09 | -$193.00K 10-Q · filed 2020-11-09 | -$290.00K derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$193.00K 10-Q · filed 2020-08-06 | -$290.00K derived: sum of 3 quarters · filed 2020-08-06 | -$403.00K derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | -$189.00K 10-Q · filed 2020-05-11 | -$286.00K derived: sum of 2 quarters · filed 2020-05-11 | -$399.00K derived: sum of 3 quarters · filed 2020-05-11 | -$398.00K derived: sum of 4 quarters · filed 2020-05-11 | |
| 2018-12-31 | -$97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$210.00K derived: sum of 2 quarters · filed 2020-03-11 | -$209.00K derived: sum of 3 quarters · filed 2020-03-11 | -$675.00K 10-K · filed 2020-03-11 | |
| 2018-09-30 | -$113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$112.00K derived: sum of 2 quarters · filed 2019-11-07 | -$578.00K 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$465.00K 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | -$466.00K 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | $0.00 10-K · filed 2019-03-08 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-03-08 | ||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-10 | ||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-14 | ||||
| 2015-03-31 | $52.00K 10-Q · filed 2016-05-10 | ||||
| 2014-12-31 | $307.00K 10-K · filed 2017-03-14 | $44.80M 10-K · filed 2015-03-13 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-14 | $653.00K 10-K · filed 2014-03-17 | |||
| 2012-12-31 | $378.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |